NCLT Chandigarh allows Fortis to withdraw SRL demerger scheme

The National Company Law Tribunal bench in Chandigarh has allowed Fortis Healthcare to withdraw its scheme to demerge SRL diagnostics from the group and merge it with its step down subsidiary, the company told stock exchanges on Friday.

Fortis wanted to withdraw the composite scheme of arrangement and amalgamation between the group, Fortis Malar Hospitals and SRL due to reasons beyond the its control and its recently launched fresh bidding process for a deal.

The process was to take 6-8 months but has taken over 19 months and is still not complete, the company told BSE on Thursday.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

    Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

    Top 30 pharma companies post 12% revenue growth in first nine months

    Top 30 pharma companies post 12% revenue growth in first nine months

    India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory

    India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory

    Ludhiana police seize 56 kg ganja; courier warehouse under scanner

    Ludhiana police seize 56 kg ganja; courier warehouse under scanner

    AsterDMHealthcare-QCIL Merger mirrors Overwhelming Trust in Leadership

    AsterDMHealthcare-QCIL Merger mirrors Overwhelming Trust in Leadership

    DCGI asks drugmakers to stop GLP-1 obesity awareness ad campaigns

    DCGI asks drugmakers to stop GLP-1 obesity awareness ad campaigns